New HIV drug LP-98 tested in humans for first time

NCT ID NCT05933824

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This first-in-human study tested a single dose of LP-98 injection in 36 healthy adults to see if it is safe and how the body processes it. Participants received either LP-98 or a placebo by injection under the skin or into a vein. The study is complete, but it only looked at safety and immune response, not whether LP-98 can prevent or treat HIV.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

LP-98 injection

What this could lead to

If successful, this early research could pave the way for a new HIV prevention or treatment option.

What could go wrong

This is a very early, small trial in healthy people, not those with HIV. It only checks safety and dosing, not whether LP-98 works against the virus. Many early-stage drugs fail to show benefit later.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Henan Provincial Hospital for Infectious Diseases (Zhengzhou Sixth People's Hospital)

    Zhengzhou, Henan, 450000, China